linjc16/ctgov huggingface dataset:
Nasal Spray With Glucose Oxidase Preventing Common Cold in Pre-school Children

Study Overview
=================
Brief Summary
-----------------
To investigate if use of glucosoxidas nasal spray can reduce the number of days with upper respiratory tract infections in children beyond 4 years.

Detailed Description
-----------------
Children below 4 years of age and in public day care were invited to participate in this prospective study. The children started with a visit to an ENT doctor and after inclusion the children started to spray twice daily with glucose oxidase+glucose or only saline+glucose for 3 months. During this period the parents were asked to fill in a home protocol recording upper respiratory tract symptoms as: rhinitis, cough, fever, ear ache. After 6 weeks and 12 weeks the children had scheduled visits to the ENT department, where an ENT doctor examined the throat, nasal cavity and the ear drums for otitis media. After 12 weeks of treatment a nasopharyngeal swab was taken for bacterial culture.

Official Title
-----------------
Placebo Controlled Study Among Children Below Four Years of Age, Investigating Whether a Glucose Oxidase Nasal Spray Can Reduce Days With Upper Respiratory Tract Infection Symptoms

Conditions
-----------------
Upper Respiratory Tract Infections

Intervention / Treatment
-----------------
* Drug: Placebo
* Drug: Glucose oxidase


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children below 4 years of age Exclusion Criteria: None

Ages Eligible for Study
-----------------
Maximum Age: 3 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo: Saline+glucose nasal spray<br>Subjects received nasal spray containing both saline+glucose twice daily for 3 months | Drug: Placebo<br>* placebo containing saline+glucose<br>* Other names: Baxter Rehydrex;|
| Active Comparator: Nasal spray with glucose oxidase+glucose<br>Nasal spray in a bag-on-valve device with 50U/ml containing both glucose oxidase + 5% glucose in isotone saline. Dosage: One puff in each nostril twice daily for 3 months. | Drug: Glucose oxidase<br>* a hydrogen peroxide producing enzyme that creates an acidous environment to which rhinoviruses are sensitive.<br>* Other names: G2133, Sigmaaldrich;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Respiratory Infectious Symptoms | Days with upper respiratory tract infection symptoms during a 3 months period are recorded in a home protocol by the parents of the children. | 3 months of recording | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Days with URTI symptoms
Serum Folic Acid Levels in Preterm Infants

Study Overview
=================
Brief Summary
-----------------
Therefore preterm infants must need folic acid replacement than term babies.

Detailed Description
-----------------
All babies need to different vitamin supplementation. Especially preterm infants need some vitamin supplements. Folic acid is very important structure of part of cell growing.ın theorically; preterm infants have very rapid cell reproduction capacity than term infants. Therefore preterm infants must need folic acid replacement than term babies. The investigators want to determine preterm infants folic acid levels due to gestational age whether needs folic acid replacement.

Official Title
-----------------
Zekai Tahir Burak Maternity and Teaching Hospital

Conditions
-----------------
Very Low Birth Weight Baby

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: -All preterm infants Exclusion Criteria: -Major congenital anomaly

Ages Eligible for Study
-----------------
Minimum Age: 24 Weeks
Maximum Age: 34 Weeks

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Extremely low birth weight<br>Extremely low birth weight under 1000 gram | |
| Very low birth weight<br>Between 1000-1500 gram babies | |
| Low birth weight<br>Between 1500-2500 gram | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Folic acid replacement, Folic acid, Preterm neonate
Low Dose Estriol With Lactobacilli Treatment for Preventing Recurrent Urinary Tract Infection in Postmenopausal Women

Study Overview
=================
Brief Summary
-----------------
Recurrent urinary tract infections (UTI) are a problem for postmenopausal women. The aim of this trial is to evaluate the effectiveness of lactobacilli in combination with low dose estriol for preventing recurrent urinary tract infections in postmenopausal women.

Official Title
-----------------
Low Dose Estriol With Lactobacilli (Gynoflor) Treatment for Preventing Recurrent Urinary Tract Infection in Postmenopausal Women: A Randomized, Open, Parallel-Group Study

Conditions
-----------------
Urinary Tract Infections

Intervention / Treatment
-----------------
* Drug: Gynoflor E (low dose estriol with lactobacillus)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Postmenopausal woman History of urinary tract infection Agree to abstain from self-medication with antibiotics for UTI symptoms Agree to abstain from the use of any other intra-vaginal product Capable of providing informed consent Exclusion Criteria: Ovarian cancer, cervical cancer, breast cancer Estrogen treatment within last 2 years Vaginal bleeding Antibiotic therapy fewer than three days prior to randomization visit Known congenital urologic or gynecologic abnormalities Indwelling urinary catheter Thromboembolic disease Uncompensated liver disease Immunosuppressive drug within 60 days

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Gynoflor<br> | Drug: Gynoflor E (low dose estriol with lactobacillus)<br>* The medication, in the form of one vaginal tablet, is administered in the evenings for 18 days<br>* Other names: Gynoflor E vaginal tablet;|
| No Intervention: Control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of urinary tract infection |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| vaginal pH |  | 6 months | 
| lactobacillus colonization |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
urinary tract infections, postmenopause, lactobacillus, estriol
New Stent Retriever, VERSI System for AIS

Study Overview
=================
Brief Summary
-----------------
To confirm efficacy and safety of VERSI system for acute ischemic stroke

Detailed Description
-----------------
Efficacy; TICI 2a or more recanalization upto 3 pass of study device Safety; symptomatic intracranial hemorrhage within 24 hours of procedure

Official Title
-----------------
Efficacy and Safety of VERSI System for Acute Ischemic Stroke

Conditions
-----------------
Acute Ischemic Stroke

Intervention / Treatment
-----------------
* Device: thrombectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: onset to treat within 8 hours NIHSS 8 or more ASPECTS 5 or more Target vessel is ICA, MCA, VA, BA, PCA non-eligible or failed IV rt-PA Exclusion Criteria: known hemorrhagic tendency arterial dissection, vasculitis allergy for contrast media other inappropriate condition

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Device Feasibility
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: thrombectomy<br>thrombectomy by Versi system | Device: thrombectomy<br>* mechanical thrombectomy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of treatment-related severe adverse event | symptomatic intracranial hemorrhage | within 24 hours after procedure | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| recovery to independent life {modified Rankin score of 2 or less] | Proportion of subjects who have modified Rankin Scale (mRS) score of 2 or less | 90days after procedure | 
| all intracralnial hemorrhage | incidence of symptomatic and asymptomatic intracranial hemorrhage | within 24 hours after procedure | 
| acceptable clinical outcome | Proportion of subjects who have modified Rankin Scale (mRS) score of 2 or less or back to baseline of mRS | 90days after procedure | 
| Severe adverse event related to device | Any severe adverse event related to device | within 24 hours after procedure | 
| recanalization ability of device | rate of immediate reperfusion with the device upto 3 path measured using Thrombolysis in Cerebrovascular Infarction (TICI) score of 2b or greater | immediatry after procedure |
The Effect of the Combined Use of Naloxone and Tramacet on Postoperative Analgesia in the Elderly

Study Overview
=================
Brief Summary
-----------------
Ten patients 70 years and older having elective total hip/knee replacement surgery will be recruited to receive a continuous IV infusion of naloxone and oral tramacet for analgesia. Postoperative analgesia, satisfaction, side effects, need for rescure analgesia, and length of stay.

Official Title
-----------------
The Effect of the Combined Use of Naloxone and Tramacet on Postoperative Analgesia in Elderly Patients Having Joint Replacement Surgery: a Prospective Feasibility Study

Conditions
-----------------
Arthroplasty

Intervention / Treatment
-----------------
* Drug: tramacet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aged 70 years or older able to give consent able to communicate in English having elective hip/knee arthroplasty ASA physical status 1-3 Exclusion Criteria: allergies to any of the following: naloxone, tramacet, NSAIDs, sulpha, or local anesthesic contraindication to spinal anesthesia contraindication to use of tramacet or celebrex ASA physical status4 chronic opiod use chronic pain syndrome

Ages Eligible for Study
-----------------
Minimum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>comibined use of tramacet and naloxone infusion perioperatively | Drug: tramacet<br>* 2 tablets every 6 hours for 5 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| opoid use post knee/hip arthroplasty |  | post-op period | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of visual analogue scale scores greater than 4 |  | post-op period | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
analgesia, hip arthroplasty, knee arthroplasty
Prospective Cohort Study of the Risk of Recurrent Atrial Fibrillation After Radiofrequency Ablation

Study Overview
=================
Brief Summary
-----------------
In this study, the continuous inclusion of atrial fibrillation patients treated by catheter ablation in the Department of Cardiology, Peking University Third Hospital, through the collection of clinical data and outpatient follow-up, to explore the risk factors of atrial fibrillation recurrence after catheter ablation and the influencing factors of major clinical events in atrial fibrillation patients, and further guide the management mode of atrial fibrillation patients.

Official Title
-----------------
Prospective Cohort Study of the Risk of Recurrent Atrial Fibrillation After Radiofrequency Ablation

Conditions
-----------------
Atrial Fibrillation

Intervention / Treatment
-----------------
* Other: After radiofrequency ablation of atrial fibrillation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1) Age > 18 2) ECG or holter electrocardiogram confirmed atrial fibrillation Exclusion Criteria: 1) Hematological diseases, autoimmune diseases and malignant tumors 2) Immobility caused by hemiplegia or severe trauma 3) The expected survival time is less than 2 years 4) Stage 4 or 5 chronic renal insufficiency (eGFR<30) 5) Poor compliance and high risk of expected loss of follow-up 6) Disorders of consciousness or Alzheimer's disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| atrial fibrillation<br>After radiofrequency ablation of patients with atrial fibrillation | Other: After radiofrequency ablation of atrial fibrillation<br>* This study imposed an intervention. Clinical data were obtained by telephone or outpatient follow-up.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compound cardiovascular event | Stroke, hemorrhage, re-hospitalization for atrial fibrillation and heart failure, and all-cause death | 24 months |
Conversion Rate of (TST) Tuberculin Skin Test and Quantiferon-TB Gold In Tube Assay in Health Care Workers

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to access conversion rate of TST (Tuberculin skin test) and Quantiferon-TB Gold In tube assay in health care workers.

Official Title
-----------------
Conversion Rate of TST and Quantiferon-TB Gold In Tube Assay in Health Care Workers

Conditions
-----------------
Tuberculosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 20-75, men and women participant who was enrolled in the study of latent tuberculosis in health care worker (IRB No.4-2009-0187) high risk or low risk health care worker who was performed TST or Quantiferon-TB Gold In tube assay before Exclusion Criteria: age < 20 person who don't agree with enrollment illiterate person who is diagnosed as active tuberculosis now person who has history of hypersensitivity on PPD (tuberculin purified protein derivative) pregnant woman person who is treated as active tuberculosis

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Health care workers<br>health care workers who performed TST or Quantiferon-TB Gold In tube assay before | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| conversion rate of latent tuberculosis infection in hospital workers |  | 3months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
latent tuberculosis in health care workers
Inspiratory Flow Using the Osmohaler

Study Overview
=================
Brief Summary
-----------------
The OsmohalerTM is a registered device in Australia. It is used to deliver a dry powder a commercial preparation of mannitol registered as AridolTM to test if a person has irritable airways such as active asthma. The overseas regulatory authorities need to know that people of all ages can achieve an adequate inspiratory flow through this device during a controlled deep inspiration. Adequate flow is generally regarded as greater than 30 litres per minute in children and 60 litres per minute in adults. The OsmohalerTM is a device with low resistance and is already in use in Australia to deliver mannitol. However there is a need to document inspiratory flows through the device during a controlled deep inspiration. The protocol requires subjects to perform a controlled deep inspiration from the device on three or five occasions. No substance will be inhaled.

Official Title
-----------------
Inspiratory Flow and VOlumes in Asthmatic and Healthy Individuals Using the Osmohaler

Conditions
-----------------
Asthma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: has asthma or is healthy aged 6 to 69 years inclusive FEV1 >/= 70% predicted Exclusion Criteria: has condition contraindicating performance of spirometrt

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 69 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Asthmatic, healthy
Efficacy of Selective Laser Trabeculoplasty in Patients Under Treatment With Topical Prostaglandines

Study Overview
=================
Brief Summary
-----------------
Retrospective analysis of efficacy of selective laser trabeculoplasty in patients under treatment with topical prostaglandins compared to patients without topical prostaglandins is performed. Inclusion criterion are patients with glaucoma or ocular hypertension, who underwent treatment with selective laser trabeculoplasty due to insufficient control of intraocular pressure during their routine treatment at the University Hospital Zurich / Division of Ophthalmology.

Conditions
-----------------
Glaucoma, Ocular Hypertension

Intervention / Treatment
-----------------
* Device: Selective Laser Trabeculoplasty


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Patients with ocular hypertension or glaucoma who underwent selective laser trabeculoplasty due to insufficient control of intraocular pressure despite maximum tolerated topical treatment. Exclusion criteria: Optic neuropathy other than glaucoma

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PGA<br>Patients under glaucoma treatment with prostaglandines | Device: Selective Laser Trabeculoplasty<br>* trabeculoplasty with an SLT-Laser to reduce intraocular pressure<br>* Other names: SLT-Laser, Tango Laser, Ellex Medical Pty. Ltd., 82 Gilbert Street, Adelaide, SA 5000 Australia;|
| NON-PGA<br>Patient not recieving prostaglandines to treat their glaucoma | Device: Selective Laser Trabeculoplasty<br>* trabeculoplasty with an SLT-Laser to reduce intraocular pressure<br>* Other names: SLT-Laser, Tango Laser, Ellex Medical Pty. Ltd., 82 Gilbert Street, Adelaide, SA 5000 Australia;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IOP |  | t0 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Glaucoma and Ocular Hypertension